SCHEMBL10160099

SCHEMBL10160099

COC(=O)c1cccc(CNC(=O)Nc2ccccc2)c1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 3/20 0.77
NAMPT P43490 3/20 0.62
SENP1 Q9P0U3 1/20 0.60
CASR P41180 1/20 0.59
RAB9A P51151 5/20 0.59
NPC1 O15118 3/20 0.59
HPGD P15428 2/20 0.57
MAPT P10636 2/20 0.57
ALDH1A1 P00352 2/20 0.57
MEN1 O00255 1/20 0.56
TP53 P04637 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
LOXL2 Q9Y4K0 1/20 0.55
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
SLC7A5 Q01650 1/20 0.54
CYP4F2 P78329 1/20 0.54
CYP4A11 Q02928 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10160169 0.86 HIF1A (0.74) HIF1ANAMPTCASRRAB9ANPC1
SCHEMBL306396 0.85 ROCK2 (0.69) HIF1ANAMPTSENP1MAPTALDH1A1
SCHEMBL28559306 0.85 NPC1 (0.72) HIF1ANAMPTRAB9ANPC1HPGD
SCHEMBL2704691 0.84 MAPT (0.66) HIF1ANAMPTRAB9ANPC1HPGD
SCHEMBL16127714 0.83 KDM4E (0.76) HIF1ARAB9ANPC1HPGDMAPT
SCHEMBL15761753 0.83 HIF1A (0.85) HIF1ASENP1RAB9AHPGDALDH1A1
SCHEMBL13501297 0.83 MMP13 (0.61) HIF1ARAB9AHPGDMEN1KMT2A
SCHEMBL15600305 0.83 LOXL2 (0.64) HIF1ASENP1RAB9ANPC1HPGD
SCHEMBL19577671 0.80 NPC1 (0.70) NAMPTRAB9ANPC1HPGDMAPT
SCHEMBL19634740 0.80 LOXL2 (0.64) HIF1ANAMPTRAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093266-B2 Rho kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-10 US disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041645-A1 RHO KINASE INHIBITORS CIT, ROCK1, RHOT2 HIF1A 2666/4885NAMPT 2698/4885SENP1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.